Login / Signup

High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.

Stefan FeitenGeothy ChakupurakalHans Peter FeustelMichael MaasbergBurkhard OtrembaPeter EhscheidtManfred HenselRichard HansenRudolf Weide
Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)
Myeloma patients seem to be highly adherent to IMID treatments.
Keyphrases
  • multiple myeloma
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • healthcare
  • primary care
  • prognostic factors
  • metabolic syndrome
  • adipose tissue
  • replacement therapy